The estimated Net Worth of Eric Bjerkholt is at least $117 ezer dollars as of 27 March 2024. Mr. Bjerkholt owns over 2,000 units of Cerus stock worth over $28,700 and over the last 19 years he sold CERS stock worth over $21,999. In addition, he makes $66,000 as Independent Director at Cerus.
Eric has made over 23 trades of the Cerus stock since 2007, according to the Form 4 filled with the SEC. Most recently he bought 2,000 units of CERS stock worth $49,600 on 27 March 2024.
The largest trade he's ever made was buying 238,243 units of Cerus stock on 30 June 2010 worth over $66,708. On average, Eric trades about 7,293 units every 94 days since 2005. As of 27 March 2024 he still owns at least 14,000 units of Cerus stock.
You can see the complete history of Mr. Bjerkholt stock trades at the bottom of the page.
Eric H. Bjerkholt serves as Independent Director of the Company. Mr. Bjerkholt has been the Chief Financial Officer of Aimmune Therapeutics, Inc., a biotechnology company developing treatments for food allergies. From 2004 until April 2017, Mr. Bjerkholt held various roles at Sunesis Pharmaceuticals, Inc., a biopharmaceutical company developing oncology therapeutics, including as Executive Vice President, Corporate Development and Finance and Chief Financial Officer. From 2002 to 2004, he was Senior Vice President and Chief Financial Officer at IntraBiotics Pharmaceuticals, Inc., a biopharmaceutical company that was acquired by Ardea Biosciences, Inc. in 2006. Mr. Bjerkholt was a co-founder of LifeSpring Nutrition, Inc., a nutraceutical company, and from 1999 to 2002 served at various times as its Chief Executive Officer, President, and Chief Financial Officer. From 1990 to 1997, he also served as a vice president in the healthcare banking group at J.P. Morgan & Co. Incorporated, an international banking firm. He has served on the boards of directors of several publicly traded companies, including as a member of the board of directors and chair of the audit committee of Corium International, Inc. until its acquisition by Gurnet Point Capital in November 2018, and as a member of the board of directors and as chair of the audit committee of StemCells, a biotech company, until its November 2016 acquisition by Microbot Medical Ltd. He holds a Cand. Oecon degree in Economics from the University of Oslo and an M.B.A. from Harvard Business School.
As the Independent Director of Cerus, the total compensation of Eric Bjerkholt at Cerus is $66,000. There are 12 executives at Cerus getting paid more, with William Greenman having the highest compensation of $3,270,180.
Eric Bjerkholt is 60, he's been the Independent Director of Cerus since 2018. There are 6 older and 6 younger executives at Cerus. The oldest executive at Cerus Corp. is Laurence Corash, 76, who is the Chief Scientific Officer.
Eric's mailing address filed with the SEC is C/O CERUS CORP, 1220 CONCORD AVE, CONCORD, CA, 94520.
Over the last 21 years, insiders at Cerus have traded over $5,083,598 worth of Cerus stock and bought 1,382,745 units worth $4,903,526 . The most active insiders traders include William Mariner Greenman, Laurence M Corash és Bruce C Cozadd. On average, Cerus executives and independent directors trade stock every 33 days with the average trade being worth of $90,805. The most recent stock trade was executed by Kevin Dennis Green on 3 September 2024, trading 82,657 units of CERS stock currently worth $178,539.
cerus corporation is a biomedical products company focused on commercializing the intercept blood system to enhance blood safety. the intercept system is designed to reduce the risk of transfusion-transmitted diseases by inactivating a broad range of pathogens such as viruses, bacteria and parasites that may be present in donated blood. the nucleic acid targeting mechanism of action enables intercept treatment to inactivate established transfusion threats, such as hepatitis b and c, hiv, west nile virus and bacteria, and is designed to inactivate emerging pathogens such as influenza, malaria and dengue. cerus currently markets and sells the intercept blood system for both platelets and plasma in europe, russia, the middle east and selected countries in other regions around the world. the intercept red blood cell system is in clinical development.
Cerus executives and other stock owners filed with the SEC include: